FOR INVESTORS

Disease outmatched by the science of degradation

FOR INVESTORS

Disease outmatched by the science of degradation

FOR INVESTORS

Disease outmatched by the science of degradation

Nurix is a biopharmaceutical company accelerating development of medicines based on targeted protein degradation, the next frontier to outmatch cancer and autoimmune diseases.

More About Nurix

View All

Minimum 15 minutes delayed. Source: LSEG

SEC Filings

March 06, 2026

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

424B5
View HTML
0001193125-26-096717.pdf
0001193125-26-096717.rtf
0001193125-26-096717.xls
XML - XBRL INSTANCE DOCUMENT

March 06, 2026

Report of unscheduled material events or corporate event

8-K
View HTML
0001193125-26-096734.pdf
0001193125-26-096734.rtf
0001193125-26-096734.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

March 02, 2026

Filed by "insiders" prior intended sale of restricted stock.

144
View HTML
0001950047-26-001992.pdf
0001950047-26-001992.rtf
0001950047-26-001992.xls

View All

Disease outmatched by the science of degradation

Disease outmatched by the science of degradation

Disease outmatched by the science of degradation

News

Events

44th Annual J.P. Morgan Healthcare Conference

Webcast to Discuss Data Presented at 67th American Society of Hematology (ASH) Annual Meeting

Piper Sandler 37th Annual Healthcare Conference

SEC Filings

Inside The Science

Advancing Our Pipeline

Learn About Us

Work at Nurix

For Investors

For Patients